NQTrp (Cat No.:I011187) is a synthetic small molecule designed to inhibit the aggregation of amyloidogenic proteins, particularly amyloid-β (Aβ) and α-synuclein, which are implicated in Alzheimer’s and Parkinson’s diseases, respectively. NQTrp binds to misfolded protein intermediates, preventing fibril formation and promoting non-toxic aggregation pathways. It has shown neuroprotective effects in various in vitro and in vivo models by reducing amyloid toxicity, oxidative stress, and inflammation. As a promising lead compound, NQTrp is widely used in neurodegenerative disease research focused on therapeutic strategies targeting protein misfolding and aggregation.